Paragon Capital Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 200 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

A number of other large investors have also added to or reduced their stakes in GWPH. Mckinley Capital Management LLC Delaware bought a new stake in shares of GW Pharmaceuticals PLC- in the 4th quarter valued at approximately $30,000. Resources Investment Advisors Inc. grew its stake in shares of GW Pharmaceuticals PLC- by 51.9% in the 4th quarter. Resources Investment Advisors Inc. now owns 366 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 125 shares in the last quarter. Horrell Capital Management Inc. grew its stake in shares of GW Pharmaceuticals PLC- by 33.3% in the 4th quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 100 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of GW Pharmaceuticals PLC- in the 4th quarter valued at approximately $48,000. Finally, Advisory Services Network LLC grew its stake in shares of GW Pharmaceuticals PLC- by 23.1% in the 4th quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 96 shares in the last quarter. 79.42% of the stock is currently owned by institutional investors.

In other news, CEO Justin D. Gover sold 22,620 shares of the company’s stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $12.50, for a total transaction of $282,750.00. Following the completion of the transaction, the chief executive officer now directly owns 370,445 shares in the company, valued at $4,630,562.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Cabot Brown sold 52,104 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $14.38, for a total value of $749,255.52. Following the transaction, the director now owns 21,679 shares of the company’s stock, valued at $311,744.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,895,496 shares of company stock valued at $27,538,565. Corporate insiders own 5.50% of the company’s stock.

Several equities research analysts recently commented on GWPH shares. ValuEngine cut GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, February 6th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $193.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, February 27th. Finally, Guggenheim started coverage on GW Pharmaceuticals PLC- in a research report on Friday, February 22nd. They set a “buy” rating and a $178.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $180.27.

GW Pharmaceuticals PLC- stock traded down $3.43 during trading hours on Monday, reaching $164.39. 419,442 shares of the company were exchanged, compared to its average volume of 478,387. The stock has a market capitalization of $5.06 billion, a P/E ratio of -15.57 and a beta of 2.80. The company has a quick ratio of 6.34, a current ratio of 6.66 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 12 month low of $90.14 and a 12 month high of $182.23.

ILLEGAL ACTIVITY WARNING: “Paragon Capital Management LLC Buys New Position in GW Pharmaceuticals PLC- (GWPH)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/paragon-capital-management-llc-buys-new-position-in-gw-pharmaceuticals-plc-gwph/2964562.html.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: The basics of gap trading strategies

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.